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Abstract
Introduction: Gastroenteropancreatic (GEP) and bronchopulmonary (BP) neurendocrine neoplasms (NENs) are rare and slowly growing 
tumours. Matrix metalloproteinases (MMPs) degrade extracellular matrix and are responsible for invasion and metastasis. Tissue inhibitors 
of matrix metalloproteinases (TIMPs) affect the invasiveness of tumour cells and the formation of distant metastases. The aim of this study 
was to evaluate selected MMPs (MMP2 and MMP9) and their tissue inhibitors (TIMP1 and TIMP2) depending on the pTNM classification, 
grading, and the occurrence of metastases.
Material and methods: The study group consisted of 86 patients with GEP NENs. The control group consisted of 31 healthy volunteers. 
Serum levels of TIMP1, TIMP2, MMP2 and MMP9 were determined by ELISA (R&D Systems) in all the study subjects. The statistical 
calculations were performed using MedCalc.
Results: We observed significant differences in MMP2 and TIMP1 levels between the study group with NENs and the control group. 
TIMP1 levels were significantly higher in patients with high-grade NEN (NEC, neuroendocrine carcinoma) compared to patients with 
low-grade tumour (NET G1, neuroendocrine tumours G1) (p < 0.017). We also observed a significant correlation between TIMP1 levels 
and the presence of metastases in the group of patients with GEP NENs, and also higher TIMP1 levels than those in the patients without 
metastases (p < 0.05). We also found a higher likelihood of metastases in patients with GEP NENs with TIMP1 levels exceeding 206.4 ng/mL.
Conclusions: Patients with NENs secreted larger quantities of MMP2 and TIMP1. TIMP1 may be considered a marker of metastases in 
patients with GEP NENs. (Endokrynol Pol 2012; 63 (6): 470–476)
Key words: neuroendocrine neoplasms, tissue inhibitors of matrix metalloproteinases, metalloproteinases, metastases
Streszczenie
Wstęp: Nowotwory neuroendokrynne (NEN) układu pokarmowego (GEP) i płuc (BP) należą do rzadkich i wolno rosnących nowotwo-
rów. Metaloproteinazy macierzy zewnątrzkomórkowej (MMPs) mają zdolność degradacji macierzy zewnątrzkomórkowej oraz są odpo-
wiedzialne za inwazje i powstawanie przerzutów. Tkankowe inhibitory metaloproteinaz (TIMPs) wpływają na inwazyjność komórek 
nowotworowych, redukcję wzrostu guza i tworzenia przerzutów odległych. Celem pracy była ocena stężeń wybranych metaloproteinaz 
(MMP2 i MMP9) i ich tkankowych inhibitorów (TIMP1 i TIMP2) w zależności od klasyfikacji pTNM, stopnia zróżnicowania nowotworu 
oraz występowania przerzutów.
Materiał i metody: Grupę badaną stanowiło 86 chorych z GEP NEN, a grupę kontrolną 31 zdrowych ochotników. U wszystkich badanych 
wykonano oznaczenia stężeń TIMP1, TIMP2, MMP2, MMP9 w surowicy krwi metodą ELISA (R&D System). Obliczeń statystycznych 
dokonano za pomocą programu MedCalc. 
Wyniki: W grupie badanej z NEN zaobserwowano znamienne różnice w stężeniu MMP2 i TIMP1 w porównaniu z grupą kontrolną. 
Stężenie TIMP 1 było znamiennie wyższe u chorych z rakiem neuroendokrynnym (NEC) w porównaniu z grupą z NET G1 (p < 0,017). 
Zaobserwowano również istotną korelacje pomiędzy stężeniem TIMP 1 a obecnością przerzutów w grupie chorych z GEP NEN oraz 
wyższe stężenie TIMP1 w surowicy krwi w porównaniu z chorymi bez obecności przerzutów (p < 0,05). Stwierdzono również większe 
prawdopodobieństwo wystąpienia przerzutów u chorych z GEP NEN, gdy stężenie TIMP1 wynosiło powyżej 206,4 ng/ml. 
Wnioski: U chorych z NEN występuje zwiększone wydzielanie MMP2 i TIMP1. TIMP 1 może być rozpatrywany jako wskaźnik świadczący 
o wystąpieniu przerzutów u chorych z GEP NEN. (Endokrynol Pol 2012; 63 (6): 470–476)
Słowa kluczowe: nowotwory neuroendokrynne, inhibitory tkankowe metaloproteinaz, metaloproteinazy, przerzuty
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Introduction
Gastroenteropancreatic neuroendocrine neoplasms 
(GEP NENs) are a heterogenous group of slow grow-
ing tumours originating in the diffuse neuroendocrine 
system. GEP NENs remain clinically latent for years and 
the diagnosis is most commonly established when the 
disease is already disseminated [1–3]. The histological 
and pathological staging of the tumours in patients with 
GEP NENs is based on the assessment of the tumour size 
(T), the presence of nodal metastases (N), and presence 
of distant metastases (M).
There is an ongoing search for new markers that 
will help to establish the diagnosis and prognosis and 
to monitor treatment. Most of the existing markers 
are used to monitor patients already diagnosed with 
cancer, as they do not meet the stringent criteria that 
would enable them to be used in the diagnostic process 
(i.e. low sensitivity and specificity in early disease) [4]. 
Non-specific markers of NENs include: chromogranin 
A (CgA) and neuron-specific enolase (NSE) [5, 6].
New tumour markers that are currently being inves-
tigated include matrix metalloproteinases (MMPs) and 
tissue inhibitors of matrix metalloproteinases (TIMPs). 
MMPs are a group of proteases that are activated by zinc 
and calcium ions (Zn2+ and Ca2+, respectively) [7]. Of the 
22 MMPs identified in humans so far, MMP2 and MMP9 
exhibit proneoplastic properties and degrade various 
types of collagen, such as type IV collagen, which is the 
principal constituent of vascular basal membranes [8]. 
By degrading the elements of the extracellular matrix 
(ECM), MMP2 and MMP9 are involved in the migration 
of both endothelial and tumour cells, which results in 
the formation of new vessels and new tumour foci and 
therefore metastases [9].
TIMPs are proteins that inhibit the proteolytic activ-
ity of MMPs. They affect the invasiveness of tumour 
cells, reduce tumour size and suppress the formation 
of distant metastases, regulate growth, differentiation 
and apoptosis and, independently of the inhibition 
of MMPs, are capable of stimulating the development 
of various cells, including tumour cells (Fig. 1). Four 
types of TIMPs have so far been identified (TIMP1 to 
TIMP4). The commonest TIMPs in tissues are TIMP1 
and TIMP2 [10]. 
While the formation of TIMPs and MMPs in various 
types of tumour have been documented in numerous 
studies (Table I), no such data is available for NENs.
Figure 1. The effects of tissue inhibitors of metalloproteinases 
(TIMPs) in tumours
Rycina 1. Schemat działania tkankowych inhibitorów 
metaloproteinaz (TIMPs) w nowotworach
Table I. Comparison of serum levels of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) 
in patients with various tumours
Tabela I. Porównanie stężeń wybranych metaloproteinaz (MMPs) i ich tkankowych inhibitorów (TIMPs) w surowicy krwi 
u chorych z różnymi rodzajami nowotworów
Tumour type MMP2 MMP7 MMP9 TIMP1 TIMP2
Breast cancer [11, 12] — — — ≠ ≠
Lung cancer [13, 14] ≠ — ≠ ≠ —
Colon cancer [15, 16] — ≠ ≠ — —
Rectal cancer [17] — — — ≠ —
Stomach cancer [18, 19] — — — ≠ —
Pancreatic cancer [20, 21] ≠ — ≠ — —
Ovarian cancer [22] — — — ≠ —
Bladder cancer [23, 24] ≠ ≠ — — ≠
Prostate cancer [25] ≠ — — — —
Neuroendocrine neoplasms — — — — —
— no data available; ≠ elevated serum levels
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Searching for new markers which would be helpful 
in the diagnosis and monitoring of cancer and which 
would translate into further patient management, offers 
new options for patients with NENs. The use of MMP 
inhibitors may be a new form of therapy for these pa-
tients, as these agents may not only affect tumour size 
reduction, but also the suppression of the formation of 
distant metastases.
In order to determine the usefulness of selected 
MMPs (MMP2 and MMP9) and TIMPs (TIMP1 and 
TIMP2) in patients with GEP NENs and BP NENs:
We evaluated serum levels of selected MMPs and 
TIMPs in patients with GEP NENs and BP NENs and 
in a control group.
We compared serum levels of selected MMPs and 
TIMPs depending on the pTNM classification, grading, 
and the presence of metastases.
Material and methods
We enrolled 86 patients with the diagnosis of GEP NEN 
or BP NEN aged 25 to 85 years (mean age: 57.2 years), 
including 52 women and 34 men. Based on their clinical 
and histopathological presentation, the patients were 
subdivided into two study groups:
 — A group of patients with GEP NENs (n = 62) (Sub-
group 1)
 — A group of patients with BP NENs (n = 24) (Sub-
group 2)
The control group consisted of 31 healthy volunteers 
aged 39 to 78 years (mean age: 53.7 years).
All the subjects provided informed consent to par-
ticipate in the study. The study was approved by the 
relevant bioethics committee.
Inclusion criteria
Adults over the age of 18 years with a diagnosis of GEP 
NEN or BP NEN who provided written informed con-
sent were included in the study.
Exclusion criteria
Patients with GEP NENs or BP NENs who refused 
to provide written informed consent, patients below 
18 years of age, pregnant or breastfeeding women, pa-
tients with end-stage liver disease, patients with stage 
IV or V chronic kidney disease, patients with advanced 
heart failure, and patients with other tumours were 
excluded from the study.
Methods
Fasting blood samples for the determination of hor-
mones were collected at 8.00am from an arm vein. 
The samples were centrifuged to yield serum samples, 
which were stored at –70°C until analysis.
Levels of the following neuroendocrine tumour 
markers were determined in all the patients: chro-
mogranin A, serotonin and 5-hydroxyindoleacetic acid.
Serum levels of MMP2, MMP9, TIMP1 and TIMP2 
were determined by enzyme-linked immunosorbent as-
say (ELISA) using the Quantikine kit from R&D Systems 
GmbH, Wiesbaden-Norderstadt, Germany, at analytical 
sensitivities of 0.16 ng/mL, 0.156 ng/mL, 0.08 ng/mL and 
0.011 ng/mL, respectively.
The resulting data was subjected to statistical analy-
sis. This involved comparing data in the study groups 
and assessing its correlation with the pTNM classifica-
tion, grading and the presence of metastases.
The statistical calculations were performed using 
MedCalc. Values of measureable variables were pre-
sented as arithmetic means with standard errors of 
the mean (SEM). The distributions were checked for 
normality using the Kolmogorov-Smirnov test. The re-
lationships between normally distributed variables were 
assessed using Pearson’s correlation. The relationships 
between variables lacking normal distribution were 
assessed using Spearman’s rank correlation coefficient, 
and the differences between quantitative variables and 
qualitative variables were assessed with non-parametric 
tests: the Mann-Whitney test for two groups and the 
Kruskal-Wallis test for three or more groups. Linear 
regression curves were presented for the observed 
correlations. The differences between individual vari-
ables in specific groups were assessed using univariate 
analysis of variance.
Results
In the group of patients with GEP NENs, 52% (32/62) 
were patients with intermediate-grade NEN (NET 
G2) and 35% (22/62) with low-grade tumour (NET G1) 
according to the 2010 WHO classification. Neuroendo-
crine carcinoma (NEC) was present in 13% of the pa-
tients (8/62). We assessed and compared serum levels of 
selected MMPs (MMP2 and MMP9) and TIMPs (TIMP1 
and TIMP2) in the group of patients with NENs (n = 86) 
and in the control group (n = 31), as shown in Table II.
A similar assessment of serum levels of selected 
MMPs and TIMPs was performed in the subgroups of 
GEP NEN patients (Table III) and BP NEN patients (Ta-
ble IV). In the group of patients with GEP NENs, higher 
serum levels of TIMP1 and MMP2 versus controls were 
found (p < 0.05 for both comparisons). In the group 
of patients with BP NENs on the other hand, only the 
levels of TIMP1 were higher compared to the control 
group (p = 0.024).
Serum levels of MMP2, MMP9, TIMP1 and TIMP2 
in patients with GEP NENs and BP NENs were as-
sessed depending on the pTNM classification. The 
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largest and the smallest primary tumours in patients 
with a known primary tumour size were 60 mm and 
2 mm, respectively. Nearly half of the patients with GEP 
NENs showed lymph node involvement. In a third of 
the patients, it was not possible to determine whether 
the lymph nodes were invaded or not. Half of the pa-
tients had distant metastases. Higher values of TIMP1 
were found in patients with nodal involvement (N1) 
compared to patients in whom it was not possible to 
determine nodal status (Nx) according to the pTNM 
classification (p = 0.031). TIMP1 levels were also higher 
in the group of patients with distant metastases (M1) 
compared to patients without distant metastases (M0) 
(p = 0.016) (Fig. 2).
No statistically significant differences were shown 
in serum levels of the remaining MMPs (MMP2 and 
MMP9) and TIMP2 relative to the presence of distant 
metastases.
Serum levels of MMP2, MMP9, TIMP1 and TIMP2 
in patients with GEP NENs and BP NENs were as-
sessed relative to tumour grade. Elevated levels of 
TIMP1 were observed in patients with NEC, which 
showed statistical significance versus patients with 
G1 tumours (Fig. 3).
Table II. Comparison of serum levels of matrix metalloproteinase 2 (MMP2), matrix metalloproteinase 9 (MMP9), tissue 
inhibitor of metalloproteinase 1 (TIMP1), and tissue inhibitor of metalloproteinase 2 (TIMP2) in patients with neuroendocrine 
neoplasms (NEN, n = 86) versus controls (n = 31)
Tabela II. Porównanie stężeń metaloproteinazy 2 (MMP2), metaloproteinazy 9 (MMP9), tkankowego inhibitora 
metaloproteinazy 1 (TIMP 1), tkankowego inhibitora metaloproteinazy 2 (TIMP2) w surowicy krwi u chorych z nowotworami 
neuroendokrynnymi (NEN, n = 86)  w porównaniu z grupą kontrolną (GK, n = 31)
Study group NEN (n = 86) Control group (n = 31) p value
Mean SEM Mean SEM
MMP2 [ng/mL] 223.35 6.77 194.77 10.17 0.03
MMP9 [ng/mL] 300.27 23.49 278.49 37.76  > 0.05
TIMP1 [ng/mL] 233.91 12.84 164.68 7.32 0.002
TIMP2 [ng/mL] 111.62 2.47 103.34 3.13  > 0.05
Table III. Comparison of serum levels of matrix metalloproteinase 2 (MMP2), tissue inhibitor of metalloproteinase 1 (TIMP1), 
and tissue inhibitor of metalloproteinase 2 (TIMP2) in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP 
NEN subgroup, n = 62) versus controls (n = 31)
Tabela III. Porównanie stężeń metaloproteinazy 2 (MMP2), tkankowego inhibitora metaloproteinazy 1 (TIMP1) i tkankowego 
inhibitora metaloproteinazy 2 (TIMP2) w surowicy krwi u chorych z nowotworami neuroendokrynnymi układu pokarmowego 
(GEP NEN, n = 62) w porównaniu z grupą kontrolną (GK, n = 31)
GEP NEN subgroup (n = 62) Control group (n = 31) p value
Mean SEM Mean SEM
MMP2 [ng/mL] 228.38 8.12 194.77 10.17  < 0.05
TIMP1 [ng/mL] 246.05 16.73 164.68 7.32  < 0.05
TIMP2 [ng/mL] 112.41 3.01 103.34 3.13 0.064
Table IV. Comparison of serum levels of tissue inhibitor of metalloproteinase1 (TIMP1) and tissue inhibitor of 
metalloproteinase 2 (TIMP2) in patients with bronchopulmonary neuroendocrine neoplasms (BP NEN subgroup, n = 24) 
versus controls (n = 31)
Tabela IV. Porównanie stężeń tkankowego inhibitora metaloproteinazy 1 (TIMP1) i tkankowego inhibitora metaloproteinazy 
2 (TIMP2) w surowicy krwi u chorych z nowotworami neuroendokrynnymi płuc (BP NEN, n = 24) w porównaniu z grupą 
kontrolną (GK, n = 31)
BP NEN subgroup (n = 24) Control group (n = 31) p value
Mean SEM Mean SEM
TIMP1 [ng/mL] 206.29 17.61 164.68 7.32 0.024
TIMP2 [ng/mL] 110.18 4.62 103.34 3.13  > 0.05
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An attempt to analyse the relationship between 
selected MMPs and TIMPs and the pTNM classification 
was also made in the group of patients with BP NENs, 
but due to the insufficient size of the groups this statisti-
cal analysis was not performed.
Serum levels of MMP2, MMP9, TIMP1 and TIMP2 
in GEP NEN patients and BP NEN patients were as-
sessed relative to the presence and type of metastases. 
In more than half (36/62) of the patients with GEP 
NENs, metastases were present, with liver metastases 
being the commonest (4/5 of the patients with GEP 
NENs). Other locations of metastases included the 
lymph nodes, bone and other organs, such as the ova-
ries, cerebellum, and adrenal glands. In the group of 
BP NEN patients, metastases were present in a lower 
percentage of patients (21%). Each of the patients had 
nodal metastases. Liver metastases were observed in 
three out of 24 patients; in one out of 24 the disease 
had spread to the contralateral lung, and in one out 
of 24 to the scalp. Patients with GEP NENs without 
metastases had lower levels of TIMP1 compared to 
those with metastases (p < 0.05) (Fig. 4).
We observed a higher likelihood of metastases at 
TIMP1 levels exceeding 206.4 ng/mL (AUC 0.78, p < 
< 0.05) (Fig. 5 and 6). No such relationships were ob-
served between serum levels of the MMP2, MMP9 and 
TIMP2 in GEP NEN patients with metastases.
Due to the small size of the group of BP NEN pa-
tients with metastases (n = 5), we did not perform a sta-
tistical analysis to compare serum levels of the selected 
MMPs and TIMPs relative to the pTNM classification.
Discussion
The available bibliography contains data on overexpres-
sion of selected MMPs and TIMPs in many tumours. In 
our study, we set out to determine whether new markers 
Figure 2. Comparison of serum levels of tissue inhibitor of 
metalloproteinase 1 (TIMP1) [ng/mL] relative to the presence of 
distant metastases (M) according to the pTNM classification in 
patients with gastroenteropancreatic neuroendocrine neoplasms 
(GEP NENs, n = 62). Mx — assessment of distant metastases 
not possible. M0 — absence of distant metastases; M1 — presence 
of distant metastases
Rycina 2. Porównanie stężeń tkankowego inhibitora 
metaloproteinazy 1 (TIMP1) [ng/ml] w zależności od obecności 
przerzutów odległych (M) z uwzględnieniem klasyfikacji pTNM 
u chorych z nowotworami neuroendokrynnymi układu 
pokarmowego (GEP NEN, n = 62)
Figure 3. Comparison of serum levels of tissue inhibitor 
of metalloproteinase 1 (TIMP1) [ng/mL] in patients with 
gastroenteropancreatic neuroendocrine neoplasms (GEP NENs 
subgroup, n = 62) relative to grading
Rycina 3. Porównanie stężenia tkankowego inhibitora 
metaloproteinazy 1 (TIMP1) [ng/ml] u chorych z GEP NEN 
w zależności od stopnia zróżnicowania nowotworu (grading)
Figure 4. Comparison of serum levels of tissue inhibitors 
of metalloproteinase 1 (TIMP1) [ng/mL] in patients with 
gastroenteropancreatic neuroendocrine neoplasms (GEP NENs, 
n = 62) relative to the presence or absence of metastases
Rycina 4.  Porównanie stężeń tkankowego inhibitora 
metaloproteinazy 1 (TIMP1) [ng/ml] u chorych z nowotworami 
neuroendokrynnymi układu pokarmowego (GEP NEN, N=62) 
w stosunku do obecności przerzutów
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of NENs could be found among MMPs and TIMPs. In 
the entire study group, in GEP NEN patients and BP 
NEN patients, we found elevated serum levels of MMP2 
and TIMP1 compared to the control group. When we 
analysed serum levels of the selected MMPs and TIMPs 
in individual study groups, we found that patients with 
GEP NENs had elevated MMP2 and TIMP1 levels, while 
in BP NEN patients, only serum levels of TIMP1 were 
elevated compared to the control group. Similarly to our 
study, other studies have also shown elevated serum 
levels of MMP2 in patients with other tumours, includ-
ing pancreatic, bladder, breast and prostate cancers [20, 
24, 25] and elevated serum levels of TIMP1 in patients 
with stomach, rectal, ovarian and lung cancers [17, 18].
No data is, however, available on serum levels of 
MMPs and TIMPs in patients with NENs. There has 
been only one publication on the expression of MMPs 
and TIMPs in tissues of patients with a neuroendocrine 
tumour of the ileum. In that publication, Voland et al. 
[26] assessed, in tissues of the primary tumour, the ex-
pression of a marker of enterochromaffin (EC) cells, the 
so-called vesicular monoamine transporter 1 (VMAT-1), 
and of selected MMPs (MMP2, MMP7, MMP9, MMP11 
and MMP13) and TIMPs (TIMP1, TIMP2 and TIMP3) in 
25 patients with carcinoids originating in the EC cells, 
and compared it to the expression of these markers 
in nodal and liver metastases. The authors found in-
creased expression of VMAT-1, MMP2, MMP11, TIMP1 
and TIMP3 in tumour tissue compared to healthy 
tissues.
In a cancer, the formation of metastases is a complex, 
multistep process, determined by such factors as: pro-
teolytic activity of tumour cells, their migratory abilities, 
proliferative activity and ability to neovascularisation 
[27, 28]. Tumour cells use MMPs to form a neoplastic 
infiltrate and to migrate in the process of metastasising 
[29]. Based on numerous, studies the role of MMPs in 
disseminated disease has been confirmed [30, 31]. In-
creased expression of TIMP1 is associated with a more 
advanced stage and a more aggressive course of the 
disease [32, 33], which has been confirmed in our study. 
In the group of patients with GEP NENs but without 
metastases, we found lower serum levels of TIMP1 
compared to GEP NEN patients with metastases, which 
was confirmed in the assessment of TIMP1 levels rela-
tive to the pTNM classification of these patients. In the 
group of patients with GEP NENs, metastatic disease 
was present in 58% of the patients. The liver was the 
commonest site for metastases (83% of the patients). We 
observed higher levels of TIMP1 in the group of patients 
with GEP NENs and metastases (M1) compared to those 
without metastases (M0). We discovered that patients 
with GEP NENs were more likely to have metastases at 
TIMP1 levels exceeding 206.4 ng/mL. When we analysed 
levels of the remaining parameters in patients with GEP 
NENs with metastases, we did not find such relation-
ships. This may suggest that TIMP1 could be a helpful 
marker for the assessment of the stage of the disease. 
Similar observations to these, but with respect to other 
tumour types, have been made by Chia-Siu Wang et 
Figure 5. ROC curve illustrating the likelihood of metastases in 
patients with gastroenteropancreatic neuroendocrine neoplasms 
(GEP NENs subgroup, n = 62) relative to serum levels of tissue 
inhibitor of metalloproteinase 1 (TIMP1) (AUC 0.78)
Rycina 5. Krzywa ROC przedstawiająca prawdopodobieństwo 
wystąpienia przerzutów u chorych z nowotworami neuroendokrynnymi 
układu pokarmowego (GEP NEN, n = 62) do stężenia tkankowego 
inhibitora metaloproteinazy 1 (TIMP1) (AUC = 0,78)
Figure 6. Comparison of serum levels of tissue inhibitor 
of metalloproteinase 1 (TIMP1) [ng/mL] in patients with 
gastroenteropancreatic neuroendocrine neoplasms (GEP NENs, 
n = 62) relative to the presence or absence of metastases at the 
cutoff point for TIMP1 level of 206.4 ng/mL
Rycina 6. Porównanie stężeń tkankowe inhibitora metaloprote-
inazy TIMP1 [ng/ml] u chorych z nowotworami neuroendokryn-
nymi układu pokarmowego GEP NEN (N = 62) w zależności od 
obecności lub braku przerzutów przy punkcie odcięcia dla stężenia 
TIMP1 wynoszącego 206,4 ng/ml
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al. [18]. In a group of 170 patients with stomach cancer, 
they assessed serum levels of TIMP1 and found that it 
correlated with nodal metastases and distant metastases 
to the liver and peritoneum. The authors suggested that 
determination of TIMP1 in the serum of patients with 
stomach cancer could become a promising marker for 
determining the progression and stage of cancer. In the 
already cited study by Voland et al. [26], which assessed 
the expression of MMPs and TIMPs in primary tumour 
tissue in patients with NENs, a higher expression of 
MMP2, MMP9, TIMP1, TIMP2 and TIMP3 was found in 
patients with liver metastases (M1) compared to those 
without metastases (M0). Mroczko et al. [34] found that 
serum levels of TIMP1 in patients with colorectal cancer 
correlated with the stage of the disease, nodal involve-
ment and the presence of distant metastases.
Comparing our findings to those of Voland et al. 
[26], we showed different results, although the study 
above assessed expression of TIMP1 in primary focus of 
tumour rather than its serum levels. A lower expression 
of TIMP1 in primary tumour tissue does not rule out 
elevated serum levels of TIMP1 in these patients, which 
may result from the formation of TIMP1 by the cells of 
metastatic tumours that may show a different biological 
behaviour compared to the cells of the primary tumour.
Conclusions
Determination of serum levels of MMP2 and TIMP1 may 
be useful in NENs. Patients with NENs have increased 
secretion of MMP2 and TIMP1. TIMP1 may be consid-
ered a marker of metastases in patients with GEP NENs. 
The higher levels of TIMP1 in patients with metastases, 
and consequently with a more advanced stage of the 
disease, supports the use of this factor for prognostic 
purposes in this group of patients.
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